Excited by early data on an investigational IL-4/IL-13 receptor antibody it in-licensed in 2014, Aslan Pharmaceuticals Pte. Ltd. has agreed to pay its source, CSL Ltd., as much as $780 million for full global rights to the asset, ASLAN-004, setting aside earlier plans to collar a global partner. Instead Aslan's team now plans to pay CSL $30 million upon starting a phase III study of the drug itself, after first tackling a multiple ascending-dose study in patients with moderate to severe atopic dermatitis (AD).